Business Wire

SHIPPEO

22.5.2023 17:46:25 CEST | Business Wire | Press release

Share
Shippeo Recognized in the 2023 Gartner® Magic Quadrant™ for Real-Time Transportation Visibility Platforms

Shippeo, a global leader in real-time multimodal transportation visibility, today announced it has been recognized in the Gartner® Magic Quadrant™ for Real-time Transportation Visibility Platforms.

“I am pleased to see many of Shippeo’s recognitions over the past 12 months reflected, we believe, in our positioning in this year’s Magic Quadrant,” says Shippeo co-founder and COO, Lucien Besse.

Shippeo has a 95% willingness to recommend rating on Gartner Peer Insights™, receiving the overall rating of 4.8/5*. “These are highly important metrics for us, and reassure us that we are providing our customers with the best value, and delivering what we promise,” says Besse, adding “we believe this high customer satisfaction was helped by the fact we are the only provider to offer a triple SLA, which contractually guarantees rapid carrier onboarding, high tracking rates, and high ETA accuracy, as well as the tremendous progress we have made across all aspects of our business over the last 12 months.”

The company recently raised a record $50m in fundraising, with all existing investors taking part. “This fundraising round is the largest ever for a supply chain visibility software in Europe,” explains Besse. “It will help us bolster our sound financial position for many years to come, and accelerate our ongoing North American and APAC expansion, while giving customers and partners confidence in the longevity potential of our partnerships with the strong path to profitability we’ve laid out as a company.”

Existing investors taking part included Battery Ventures, Partech, NGP Capital, ETF Partners, Bpifrance Digital Venture and SAP.io. Notable new strategic investors include Hong Kong-based LFX Venture Partners and Japan-based Yamaha Motor Ventures, whose investment is helping to ramp up operations across Asia-Pacific, as well as Orlen VC, based in Poland, and Shift4good, a global VC fund dedicated to impact investing in smart mobility and circular economy businesses.

An expert in sustainability, Shift4good strictly invests in companies with the potential to move the needle on climate change. Beyond a strong belief in the company’s business potential, Shift4Good’s decision to invest was driven by the potential of Shippeo’s new Carbon Visibility solution to have a positive impact across the transportation and logistics sector. The emissions calculator, now generally available to all customers, combines Shippeo’s advanced visibility data capabilities with cutting edge data modeling from industry expert Searoutes, to provide extremely accurate transport and distribution GHG (CO2e) emissions reporting. The tool offers users GLEC-accredited CO2 equivalent emissions calculations, without the need to manually consolidate data supplied by carriers.

Continued expansion into North America and APAC was boosted by a new global partnership with e2open, offering Shippeo’s native real-time in-transit visibility within their comprehensive global supply chain management platform.

The company also recently welcomed some of the most iconic brands in the world, including Amazon, Barilla (US), Epson, Geodis, Jacob Douwe Egberts (JDE), Jaguar Land Rover, Lassonde, L'Oréal, Moët Hennessy (LVMH), SABIC International (the second largest public company in the Middle East) and Siemens Energy.

Over the last year, Shippeo’s team grew to more than 230 Shippians, including senior executive and SaaS veteran Philippe Vanhove as new Chief Revenue Officer, who brings 25 years of experience in scaling fast-growing, international SaaS organizations, having managed multinational sales operations, marketing, lead generation, human resources, and finance.

In April, the company launched a new biannual platform release cycle, delivering its latest Spring platform release. New and enhanced features across all transport modes introduced to users improve the platform experience and enhance visibility data quality. Highlights include a new Shippeo berth ETA as part of their Ocean Visibility offering, which is significantly more accurate and reliable than the ones received from ocean carriers, as well as new vessel AIS-based milestone detection for more accurate milestones at ports during loading, unloading and transshipment. A swathe of usability enhancements throughout the multimodal visibility platform include new container delay filters, carrier TMS tag synchronization, and configurable notifications to help users manage shipments more efficiently, by exception.

2022 also saw the launch of Shippeo’s Carrier Recognition Program, celebrating over 400 of the world’s most exceptional carriers, who provide the best service to shippers with consistently high levels of shipment tracking. The company also held their inaugural Visibility Star Awards last November, which recognize the efforts our carrier community has made to provide great service to their clients, and celebrate their exceptional commitment to real-time visibility.

More information:

*Disclaimer:
* Gartner Disclaimer: based on 214 reviews as of May 18 2023 in the Real-Time Transportation Visibility Platforms market.

Gartner “Magic Quadrant for Real-Time Transportation Visibility Platforms 2023” by Carly West, Oscar Sanchez Duran, and Nathan Lease, 16 May 2023.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, MAGIC QUADRANT and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more collaborative, automated, sustainable, profitable, and customer-centric supply chains. This is made possible with highly accurate, real-time operational visibility and perfect workflow orchestration. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and accurately measure CO2 and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Siemens Energy, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 32 million shipments per year across 110 countries. Learn more at www.shippeo.com
LinkedIn, Facebook, Twitter

About Shift4Good
Shift4Good is a venture capital fund manager dedicated to impact investing in smart mobility & circular economy start-ups. With teams based in both Paris and Singapore, Shift4Good mostly focus on European and Southeast Asian opportunities. Shift4Good can deploy between €0.5m and €20m per company and mostly invest in Series A and Series B rounds and can allocate 10% of their funds to pre-Series A rounds. More information: https://www.shift4good.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005162/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye